ORIC Pharmaceuticals, Inc. Expected to Earn Q1 2025 Earnings of ($0.47) Per Share (NASDAQ:ORIC)

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Equities research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for ORIC Pharmaceuticals in a research note issued on Monday, August 12th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.47) per share for the quarter. Wedbush currently has a “Outperform” rating and a $20.00 target price on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($1.68) per share. Wedbush also issued estimates for ORIC Pharmaceuticals’ Q4 2025 earnings at ($0.52) EPS.

ORIC has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Wednesday. Citigroup decreased their price target on shares of ORIC Pharmaceuticals from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. Oppenheimer reduced their target price on shares of ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Thursday, June 20th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, ORIC Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $19.17.

ORIC Pharmaceuticals Stock Up 9.7 %

NASDAQ:ORIC opened at $10.83 on Wednesday. The company has a market capitalization of $730.16 million, a PE ratio of -6.02 and a beta of 1.13. ORIC Pharmaceuticals has a 52-week low of $5.27 and a 52-week high of $16.65. The stock’s 50 day moving average price is $8.91 and its 200 day moving average price is $10.35.

Institutional Investors Weigh In On ORIC Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ORIC. Price T Rowe Associates Inc. MD increased its position in ORIC Pharmaceuticals by 140.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company’s stock worth $21,543,000 after purchasing an additional 915,175 shares during the period. Strs Ohio acquired a new position in ORIC Pharmaceuticals during the fourth quarter worth $72,000. AJOVista LLC acquired a new position in ORIC Pharmaceuticals during the fourth quarter worth $40,000. Vanguard Group Inc. raised its position in ORIC Pharmaceuticals by 27.9% in the first quarter. Vanguard Group Inc. now owns 2,882,055 shares of the company’s stock worth $39,628,000 after acquiring an additional 629,536 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new stake in ORIC Pharmaceuticals in the first quarter valued at $161,000. Institutional investors and hedge funds own 95.05% of the company’s stock.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.